Long Position on RGEN @ $18.15 on 5/21/2014 (Momentum)

Repligen Corporation (RGEN) develops, manufactures, and markets consumable bioprocessing products for use in the production of monoclonal antibodies and other biologic drugs.

The company manufactures various forms of Protein A, a critical reagent used in biomanufacturing to separate and purify monoclonal antibodies. It also supplies various growth factor products, which are used to increase cell growth and productivity during upstream fermentation. In addition, the company manufactures and sells chromatography products, including OPUS pre-packed columns for biologics purification, as well as proprietary Protein A media and quality test kits.

Further, it has a portfolio of therapeutic product candidates, which include RG3039, a small molecule drug candidate in clinical development for spinal muscular atrophy; histone deacetylase inhibitor for the treatment of Friedreich’s ataxia disease; and RG1068, a synthetic human hormone developed as a novel imaging agent for the detection of pancreatic duct abnormalities in combination with magnetic resonance imaging in patients with pancreatitis and other related diseases.

The company sells its bioprocessing products are to various life sciences companies, biopharmaceutical manufacturing companies, and contract manufacturing organizations worldwide.

Shares have formed a bullish "cup and handle" following the company's better than expected quarterly report. Higher share prices are expected for this stock.

52-Week Trading Range: $7.37 - $19.97

Entry Point: $18.15

Stop Loss: $17.20

Target Price: $19.97

Updates

6/5/2014 1:59:16 PM

RGEN closed at $20.30. If you elect to stay in the position, raise your stop loss to $20.

Position closed on 6/5/2014 at price of $20.30 with a 11.85% gain in 15 days.

Back to Portfolio